Yükleniyor... / Loading...
This study evaluates the drug LY2523355 (together with pegfilgrastim) in patients with ovarian cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, gastroesophageal cancer, and squamous cell carcinoma of the head and neck. Adults with measurable disease and good general condition (ECOG 0-1) were able to take part. The study was carried out in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal cancer (adenocarcinoma of the esophageal cancer, stomach, or gastroesophageal junction), or squamous cell cancer of the head and neck * Have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines (except prostate cancer participants) * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Are willing to follow study procedures for the duration of the study * Are willing to use an approved contraceptive method during treatment and for 3 months after discontinuation of study treatment Exclusion Criteria: * Have a serious preexisting medical condition that would preclude participation in the study * Are pregnant or lactating * Have received treatment within 28 days of first dose of LY2523355 with a drug that has not received regulatory approval for any indication * Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases * Have a second active primary malignancy or a history of a second malignancy requiring cytotoxic therapy * Have QTc interval greater than 470 millisecond (msec) or intraventricular conduction delay (IVCD) with QRS greater than 120 msec on screening electrocardiogram (ECG) * Have active symptomatic fungal, bacterial, and/or known viral infection including active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis * Participants with pneumonia, evidence of obstructive pneumonitis, other respiratory infections, or infection from other sources are to be excluded